Document text
Principal Investigator: Shane P Crotty
Organization: SCRIPPS RESEARCH INSTITUTE, THE
Fiscal Year: 2024
Award: $867,163
Funding agency: National Institute of Allergy and Infectious Diseases
Abstract/Project Summary
HIV-1 envelope glycoprotein (Env) is the sole target for development of antibody-mediated immune response. Studies of patients infected with HIV have led to the isolation of antibodies against different epitopes on the Env surface, capable of neutralizing a broad range of circulating HIV strains and providing passive protection against repeated viral challenges in non-human primates (NHPs). The current goal of HIV vaccine research is to create immunogens capable of eliciting similar antibody responses in naïve individuals. Structure- based engineering of the soluble ectodomain of Env trimer is in the core of most of the current approaches. One major complicating factor with this approach comes from the large antigenic surface on the Env, where many off-target and competing epitopes are available to the immune system. The induction of immune responses against “distracting” epitopes leads to attenuated and inconsistent response against the targeted bnAb epitopes of interest. NHPs are an important model for this work, because wildtype mice do not make Ab responses to major Env nAb epitopes observed in humans. Analysis of the polyclonal Ab response in NHP immunizations where soluble Env ectodomain trimers were used, revealed a set of highly immunogenic epitopes with low potential for the development of protective heterologous, and in some cases even autologous, responses. These epitopes include the base of the Env trimer ectodomain, N241/N289 glycan hole and variable loops (V1-V5). To address this shortcoming we have developed a rational approach to consistently elicit antibodies against the conserved fusion peptide (FP) epitope, for which there are several examples of human bnAbs. We have used our designer trimers and continuous antigen release program to generate preliminary results verifying success of this concept in NHPs. The reproducibility of the epitope targeting is the most impressive preliminary result presented here, and it indicates that reproducible elicitation of FP nAbs in humans may be readily achievable. Here we propose to conduct a series of experiments designed to further optimize this immunization strategy by minimizing the accessibility of immuno-distracting, off-target epitopes, and ultimately verify if protective, FP-targeting, bnAbs can be reproducibly elicited in NHPs. We intend to also immunize some animals in parallel with a SARS-CoV2 RBD immunogen we have designed. The RBD immunizations will be at a different site (deltoid) and will not interfere with the Env fusion peptide targeted immunizations. This dual use immunization approach is generally valuable for future HIV vaccine studies, and we will perform a pilot study to show this type of dual use immunization strategy is informative, which will be of value to use in our future HIV vaccine studies. The SARS-CoV2 RBD will also serve as a negative control for immunological parameters compared to the HIV candidate vaccine, which is of additional value. We will also incorporate our immunogens into multi-valent nanoparticles to improve immunogen trafficking, enhance B cell receptor avidity, and block the non-productive but highly immunogenic base epitope. Further, we will use continuous antigen delivery to improve the duration of germinal center reactions, and ultimately drive the high levels of somatic hypermutation necessary for generating bnAbs capable of neutralizing a wide diversity of HIV strains. This project will culminate by testing the efficacy of our vaccine regimen by challenging immunized NHPs with heterologous low dose repeated challenge.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><3-D><3-Dimensional><3D><7S Gamma Globulin><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Affinity><American><Animals><Antibodies><Antibody Response><Antigenic Determinants><Antigens><Attenuated><Autologous><Avidity><B blood cells><B cell><B cell receptor><B cells><B-Cell Antigen Receptor><B-Cells><B-Lymphocytes><B-cell><Binding Determinants><Blood Serum><Bolus><Bolus Infusion><Booster Immunization><COVID-19><COVID-19 vaccine><COVID-19 virus><COVID19 virus><CV-19><Cell Body><Cell Surface Glycoproteins><Cells><CoV-2><CoV2><Complex><Consensus Sequence><Coronavirus Infectious Disease 2019><Data><Deltoid><Development><Dose><Electron Microscopy><Engineering><Epitope Mapping><Epitopes><Experimental Designs><Future><Germinal Center><Glycans><Glycoproteins><Goals><Grant><HIV><HIV envelope><HIV envelope protein><HIV vaccine><HIV-1><HIV-I><HIV/AIDS Vaccines><HIV1><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Ig Somatic Hypermutation><IgG><Image><Immune response><Immune system><Immunization><Immunize><Immunochemical Immunologic><Immunoglobulin G><Immunoglobulin Somatic Hypermutation><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><Individual><LAV-HTLV-III><Left><Longitudinal Studies><Lymphadenopathy-Associated Virus><Mediating><Membrane Glycoproteins><Modeling><Modern Man><Monkeys><Needles><Pathogenicity><Patients><Peptide Vaccines><Peptide antibodies><Peptides><Pilot Projects><Polysaccharides><Public Health><Reaction><Regimen><Reproducibility><Research><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 vaccine><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SHIV><Sampling><Secondary Immunization><Series><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Structure><Structure of germinal center of lymph node><Surface><Surface Glycoproteins><Techniques><Testing><Vaccine Research><Vaccines><Viral><Virus><Virus-HIV><Wild Type Mouse><Work><Wuhan coronavirus><attenuate><attenuates><base><bases><booster vaccination><coronavirus disease 2019><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><deltoid muscle><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><efficacy testing><hCoV19><host response><human immunodeficiency virus vaccine><imaging><immune system response><immunization strategy><immunogen><immunogenic><immunoresponse><improved><interest><long-term study><longitudinal outcome studies><longterm study><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><non-human primate><nonhuman primate><novel><pandemic><pandemic disease><pilot study><polyclonal antibody><programs><protective efficacy><reconstruction><response><self assembly><simian HIV><simian human immunodeficiency virus><somatic hypermutation><success><three dimensional><trafficking><vaccination strategy><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine development><vaccine for novel coronavirus><vaccine strategy><vaccine study><vaccine trial><vaccine-related research><vaccines preventing COVID><vaccines to prevent COVID><wildtype mouse>